Back Pain News and Research

Latest Back Pain News and Research

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

Obesity, chronic pain linked to family history, mood disorders: Study

Though it is well known obese individuals have a high incidence of persistent pain problems, a new study in The Journal of Pain, published by the American Pain Society, reports that comorbid obesity and pain also are linked to family history and mood disorders.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer Inc. today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

20 Jul 2010

People needing non-emergent care can now turn to walk-in centers

For many, summer time means cook-outs, family hikes, and trips to the beach. However, while the good weather brings an increase in outdoor activities, for some it can also mean a trip to the local emergency room.

17 Jul 2010

Survey shows only few Canadians identify painful physical symptoms of depression

Although the majority of Canadians believe in a mind/body connection, agreeing how they feel physically is related to how they feel emotionally (87 per cent), only half make the link when it comes to depression.

12 Jul 2010

Medicare agency releases data on hospital performance

MedPage Today: "The public can now review data on the quality of outpatient care provided by individual hospitals at the Centers for Medicare and Medicaid Services' Hospital Compare website. The site previously contained only data on inpatient care quality. All the data are derived from records of Medicare patients treated at more than 3,600 hospitals nationwide."

9 Jul 2010

New information about quality of care available in America's hospitals added to new HHS website

Important new information about the quality of care available in America's outpatient and emergency departments, including how well hospitals care for patients with heart attacks and protect outpatients from surgical infections was added to the new HHS website HealthCare.gov.

8 Jul 2010

LBP related beliefs, behaviors affect disability more than pain intensity: Study

Approximately 10% of low back pain (LBP) sufferers experience persistent pain and significant disability. In a study published in the August issue of Pain, a group of Australian researchers investigating the relevance of health literacy in patients with chronic lower back pain (CLBP) found that LBP-related beliefs and behaviors affect a person's disability more than pain intensity or a standard measure of functional health literacy.

7 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.

2 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Majority of respondents receiving CAM therapy for back pain report great benefit: Study

A recent study, "Perceived Benefit of Complementary and Alternative Medicine for Back Pain" (Journal of the American Board of Family Medicine, May - June 2010, Vol. 23 No.3), found the majority of respondents receiving CAM for back pain reported great benefit from the various treatments.

1 Jul 2010

Herniated disk can cause low back and leg pain in adults

A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives.

30 Jun 2010

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

29 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

Literature review discusses herniated disks and treatment options for low back pain

29 Jun 2010

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.

28 Jun 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

Back Pain News and Research

Latest Back Pain News and Research

Genentech disappointed with FDA ODAC's recommendation against Avastin

Obesity, chronic pain linked to family history, mood disorders: Study

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

People needing non-emergent care can now turn to walk-in centers

Survey shows only few Canadians identify painful physical symptoms of depression

Medicare agency releases data on hospital performance

New information about quality of care available in America's hospitals added to new HHS website

LBP related beliefs, behaviors affect disability more than pain intensity: Study

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

AstraZeneca announces new support program for patients on ARIMIDEX

Majority of respondents receiving CAM therapy for back pain report great benefit: Study

Herniated disk can cause low back and leg pain in adults

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

Literature review discusses herniated disks and treatment options for low back pain

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Japan's MHLW grants full marketing authorization to REVLIMID

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in